Photo of Prof Paul O'Neill

Prof Paul O'Neill BSc Hons PhD CChem MRSC

Professor Chemistry


    Personal Statement

    Paul M. O'Neill graduated in Chemistry and Pharmacology at the University of Liverpool in 1990 and also obtained a Ph.D degree here in 1995. Following graduation, he was appointed Roche Lecturer in Medicinal Chemistry in the Department of Pharmacology at Liverpool from 1995-96. In 1997 he carried out postdoctoral research with Professor Gary H. Posner at the Johns Hopkins University, Baltimore, USA. In 1998 Paul was appointed to a lectureship between the Departments of Chemistry and Pharmacology at Liverpool and he became Senior Lecturer in 2003 and Reader in 2005.Paul works in several areas of synthetic organic chemistry and pharmacology with a strong emphasis on drug-design, chemical biology and medicinal chemistry of anti-infectives. Currently the main target diseases of the O'Neill group include malaria, TB and human filariasis in collaboration with the Liverpool School of Tropical Medicine.
    147 Publications (Google Scholar h-index = 50)

    Personal Distinctions

    • From artemisinin to tetraoxane-based antimalarial drug candidates (Invitation to Speak, 25th Annual Groupement des Pharmacochimistes de l’Arc Atlantique (GP2A), Liverpool John Moore's University 2017)
    • Antimalarial Peroxide Probe and Candidate Synthesis (Keynote Speech, Peakdale molecular 'synthesis in drug discovery and development' 4th symposium, Liverpool Hope University 2016)
    • From artemisinin to a tetraoxane-based antimalarial drug candidate that circumvents K13- dependent clinical artemisinin resistance (Keynote Speech, Bioactive Natural Products: translating promise into practice, at St Catherine’s College, Oxford University 2016)
    • Endoperoxide Antimalarial Drug Development and Mechanism of Action (Invitation to Speak, New Horizons and Emerging Biomedical Challenges for Biophysics, University of Liverpool 2016)
    • A tetraoxane-based antimalarial drug candidate that circumvents PfKelch 13-dependent artemisinin resistance (Keynote Speech, 13th Asia Pacific Federation of Pharmacologists (APFP) 2016, Bangkok Thailand 2016)
    • E209, A Novel Tetraoxane Antimalarial Candidate (Invitation to Speak, SCI Academic Drug Discovery 3, London 2015)
    • From Synthetic Endoperoxide Drug Candidates to Dual Acting Peroxide Based Hybrids (Invitation to Speak, Shanghai Institution of Organic Chemistry, Shanghai, China 2014)
    • Third Generation Tetraoxane Antimalarials (Invitation to Speak, Institution of Biomedical Sciences, Fudan, University, Shanghai, China 2014)
    • Third Generation Tetraoxane Antimalarials (H3-D Drug Discovery Symposium, Vineyard Hotel, Cape Town, South Africa, 15-18 October 2012)
    • Development of a new generation of antimalaria lead quinolones targeting the mitochondrial respiratory pathway for the treatment and prophylaxis of uncomplicated malaria (Keynote Speech, London School of Tropical medicine Hygiene, Emerging Paradigms in Anti-infective Drug Design, 17th Sept, 2012)
    • Antimalarial Drug Discovery at the University of Liverpool (Invitation to Speak, 3rd Annual Georgia Nanotechnology & Infectious Diseases Symposium, Mercer University, Atlanta , USA 2012)
    • From Candidate Selection of Synthetic Peroxides to Lead Optimisation of Quinolone Inhibitors of PfNDH2 (Invitation to Speak, UCL (London) Dept Seminar 2012)
    • Antimalarial Drug Discovery at Liverpool (Invitation to Speak, GSK Tres Cantos,Madrid, Spain 2012)
    • Drug Development of 1,2,4,5-Teraoxanes (Invitation to Speak, RSC British High Commission 2011)
    • RSC Malcolm Campbell Award (BMCS Division of The Royal Society of Chemistry, Presented at Cambridge University 2011)
    • Antimalarial Tetraoxanes; Candidate selection and back-up programme (Invitation to Speak, EU FP6 2011)
    • Update on Tetraoxane Drug Development (Invitation to Speak, St Georges Hospital, London 2010)
    • Medicinal Chemistry of Quinoline and Peroxide Antimalarials (Invitation to Speak, Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, 31077 Toulouse Cedex 4, France 2010)
    • From candidate selection of the first Tetraoxane Drug Candidate RKA 182 to the Discovery of Picomola (Keynote Speech, RSC, London School of Tropical Medicine and Hygiene 2010)
    • Antimalarial Drug Discovery in Academia; Discovery of Isoquine, FAQ4 and RKA182 (Keynote Speech, British High Commission and RSC , Singapore 2010)
    • Antimalarial Drug Discovery at the University of Liverpool (Invitation to Speak, Pfizer, Sandwich, Kent 2010)
    • From candidate selection of the first Tetraoxane Drug Candidate RKA 182 and Appropriate Back-ups (Keynote Speech, EFMC Sponsored 2nd National Conference on Medicinal Chemistry, Coimbra, Portugal 2010)
    • Synthesis in Medicinal Chemistry (Keynote Speech, Peakdale Molecular Symposium, Manchester 2010)
    • Antimalarial Drug Discovery in Academia (Keynote Speech, 1st RSC China-UK Symposium on Medicinal Chemistry, Shanghai, China 2009)
    • Synthetic Approaches to Endoperoxide Antimalarials (Invitation to Speak, SCI Conference orgnaised by the SCI Young Chemists Panel 2009)
    • Selection of RKA 182 as the first tetraoxane antimalarial drug candidate (Keynote Speech, Keystone Symposia, Breckenridge Colorado, USA 2009)
    • From the Natural Herb Qinghaosu (Artemisinin) to Orally Active Synthetic Endoperoxide Antima (Invitation to Speak, University of Bangor 2008)
    • Antimalarial Chemotherapy In the 21st Century; Advances in Drugs Targeting the Hemoglobin Degradatio (Invitation to Speak, University of Warwick 2008)
    • Advances in the Medicinal Chemistry of 4-Aminoquinolines (Invitation to Speak, ACS Conference , Boston 2007)
    • From the Natural Herb Extract Quinghaosu (Artemisinin) to Orally Active Synthetic Endoperoxide Antim (Invitation to Speak, ESB 2007)
    • Recent Advances in the Development of Drugs Targeting the Hemoglobin Degradation Pathway (Keynote Speech, ACS Medicinal Chemistry & Bioorganic Chemistry Foundation 2007)
    • The Drug Hybrid Approach to Antimalarial Chemotherapy (Invitation to Speak, ISSX 2006)
    • Evidence for a Common Iron Dependent Mechanism of Action for Diverse Endoperoxide Antimalarials (Invitation to Speak, EU COST 2006)
    • A 4-Aminoquinoline Antimalarial for the 21st Century (Invitation to Speak, (IUPHAR) Congress of Pharmacology 2006)
    • Toward a 21st Century Replacement for Chloroquine and Amodiaquine (Invitation to Speak, EU COST Initiative 2005)

    Untitled Document